Tausif Ahmed
Overview
Explore the profile of Tausif Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kollipara S, Friden M, Heimbach T, Saha P, De Backer J, Ahmed T, et al.
Pharm Res
. 2025 Mar;
PMID: 40075036
Modeling and simulation (M&S) based approaches have proven significant utility in both new drug and generic product development. Considering the plethora of applications of such novel approaches, the concept of...
2.
Mahadik K, Visala A, Chatterjee N, Pahuja M, Mehta V, Dhurde T, et al.
ALTEX
. 2025 Jan;
42(1):146-151.
PMID: 39817836
No abstract available.
3.
Khan M, Murthy A, Ahmed T
AAPS PharmSciTech
. 2024 Dec;
26(1):14.
PMID: 39690355
This review paper discusses the key aspects of ocular biopharmaceutics, with emphasis on the crucial role played by ocular compartmental modelling and simulation in deciphering physiological conditions related to various...
4.
Kollipara S, Prabhat P, Saha P, Gupta S, Naidu V, Ahmed T
AAPS PharmSciTech
. 2024 Dec;
26(1):1.
PMID: 39627629
Mesalamine is a locally acting anti-inflammatory drug used to treat mild to moderate ulcerative colitis. Because of complex formulation principle and high in vivo variability, development of bioequivalent formulation for...
5.
Rachapally A, Boddu R, Kollipara S, Ahmed T
J Pharm Sci
. 2024 Oct;
114(2):701-718.
PMID: 39414080
Orally inhaled and nasal drug products (OINDPs) are complex due to the interplay between the device, formulation, and patient characteristics. Establishing bioequivalence (BE) of OINDPs with reference is highly complex...
6.
Chougule M, Kollipara S, Mondal S, Ahmed T
Eur J Clin Pharmacol
. 2024 Oct;
80(12):1903-1922.
PMID: 39377787
Purpose: In silico modeling and simulation techniques such as physiologically based pharmacokinetic (PBPK) and physiologically based biopharmaceutics modeling (PBBM) have demonstrated various applications in drug discovery and development. Virtual bioequivalence...
7.
Bhattiprolu A, Kollipara S, Boddu R, Ahmed T
Xenobiotica
. 2024 Oct;
54(10):781-795.
PMID: 39361244
Drug products meeting the dissolution specifications is crucial in order to ensure consistent clinical performance. However, in certain cases, wider dissolution specifications may be required based on product behaviour. While...
8.
Bhattiprolu A, Kollipara S, Boddu R, Arumugam A, Khan S, Ahmed T
AAPS PharmSciTech
. 2024 Aug;
25(7):193.
PMID: 39168956
Physiologically based pharmacokinetic (PBPK) or physiologically based biopharmaceutics models (PBBM) demonstrated plethora of applications in both new drugs and generic product development. Justification of dissolution specifications and establishment of dissolution...
9.
Boddu R, Kollipara S, Kambam V, Khan S, Behera S, Murty N, et al.
Xenobiotica
. 2024 Aug;
54(9):629-641.
PMID: 39126638
The advanced simulation tools, such as physiologically based biopharmaceutics models (PBBM) or physiologically based pharmacokinetic models (PBPK), play critical role in model informed formulation development. This approach has been successfully...
10.
Kollipara S, Martins F, Jereb R, Krajcar D, Ahmed T
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065727
Bioequivalence studies are pivotal in generic drug development wherein therapeutic equivalence is provided with an innovator product. However, bioequivalence studies represent significant complexities due to the interplay of multiple factors...